GENERAL
Aurobindo Pharma Signs Licensing Agreement With MSD For HIV Drug
Aurobindo Pharma Ltd has entered into a non-exclusive voluntary licensing agreement with MSD (the trade name of Merck & Co., Inc., Rahway, New Jersey, USA) to manufacture and supply a generic version of the investigational HIV prevention medicine, Alimatravir, in eligible low- and middle-income countries. Aurobindo Pharma is among a select group of global generic […]
CW Bureau
·
Jul 25, 2026
GENERAL
India Poised To Emerge As Global Life Sciences Innovation Hub, Says Report
India is at a crucial stage in its pharmaceutical innovation journey, with the next five years likely to determine whether the country evolves from a global manufacturing powerhouse into a leading originator of breakthrough medicines, according to a joint report by Boston Consulting Group (BCG) and HealthKois. The report, titled “Built on Scale, Turning to […]
CW Bureau
·
Jul 15, 2026
GENERAL
Strides Pharma Unlocks Value From Pivot Path In Deal By Ascent Capital
Strides Pharma Science Ltd has announced a strategic investment in its wholly owned subsidiary, Pivot Path Pvt Ltd, by a consortium led by Ascent Capital along with co-investor Vintage Classic, in a transaction that values the business at ₹230 crore on a post-money basis. The deal enables Strides to realise ₹100 crore while retaining a […]
CW Bureau
·
Jun 27, 2026
GENERAL
Piramal Pharma Reports 9% Growth In Q4 Profit Before Exceptional Item
Global pharmaceutical company Piramal Pharma Ltd (PPL) reported a 9% increase in net profit before exceptional items at ₹167 crore for the March quarter compared with the year-ago period. However, the company posted a net loss of ₹9 crore after recognising an impairment loss of ₹176 crore related to intangible assets under development, following a […]
CW Bureau
·
Apr 29, 2026
HOSPITALITY
Rubicon Research To Buy 85% Stake In Arinna Lifesciences For ₹175.92 Cr
Rubicon Research Ltd has entered into definitive agreements to acquire an 85% stake in Arinna Lifesciences Ltd for a consideration of ₹175.92 crore, marking a strategic expansion in the domestic formulations market. The transaction, which values Arinna at an enterprise value of ₹200 crore on a cash and debt-free basis, is expected to be concluded […]
CW Bureau
·
Apr 15, 2026
